Morbidity and mortality of elderly patients following cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).

@article{Wong2018MorbidityAM,
  title={Morbidity and mortality of elderly patients following cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC).},
  author={Evelyn Y T Wong and Grace Hwei Ching Tan and Claramae Shulyn Chia and Mrinal Kumar and Khee Chee Soo and Melissa Ching-Ching Teo},
  journal={Asia-Pacific journal of clinical oncology},
  year={2018},
  volume={14 2},
  pages={e193-e202}
}
AIM Cytoreductive surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) is known to improve survival in selected patients with peritoneal metastasis. However, there is limited data supporting the role of CRS and HIPEC in elderly patients (≥65 years old). METHODS A retrospective review of a prospectively maintained database of patients who… CONTINUE READING